IIM
PLX icon

INTECH Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

INTECH Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.3K Sell
19,958
-11,175
-36% -$27.7K ﹤0.01% 2021
2025
Q4 		$56K Sell
31,133
-115
-0.4% -$235 ﹤0.01% 2251
2025
Q3 		$69.4K Sell
31,248
-5,242
-14% -$8.54K ﹤0.01% 2335
2025
Q2 		$54K Buy
+36,490
New +$74.7K ﹤0.01% 2413

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

INTECH Investment Management's PLX Position: Q1 2026 in Review

INTECH Investment Management reduced its Protalix BioTherapeutics (PLX) stake by 36% in Q1 2026, selling an estimated $27.7K and leaving 19,958 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2021.

INTECH Investment Management first reported a position in PLX in Q2 2025 and has held it in 4 quarters since. The position peaked at $69.4K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • INTECH Investment Management held 19,958 shares of Protalix BioTherapeutics worth $43.3K as of Q1 2026.
  • INTECH Investment Management sold 11,175 Protalix BioTherapeutics shares in Q1 2026, an estimated $27.7K.
  • Protalix BioTherapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #2021 holding.
  • INTECH Investment Management first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 4 quarters since.
  • INTECH Investment Management's Protalix BioTherapeutics position peaked at $69.4K in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.